Comparison of the Levels of Immunogenicity and Safety of Zostavax in Adults 50 to 59 Years Old and in Adults 60 Years Old or Older

Zostavax has been shown to be efficacious in the prevention of herpes zoster and generally well tolerated in clinical trials among subjects 60 years old or older. This prespecified combined analysis from two studies compares the levels of immunogenicity and safety of Zostavax in subjects 50 to 59 ye...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sutradhar, Santosh C., Wang, William W. B., Schlienger, Katia, Stek, Jon E., Xu, Jin, Chan, Ivan S. F., Silber, Jeffrey L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology (ASM) 2009
Assuntos:
Vaccine Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2681586/
https://ncbi.nlm.nih.gov/pubmed/19261769
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00407-08
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados